A Plus Biotechnology Co., Ltd. (TPE:6918)

Taiwan · Delayed Price · Currency is TWD

75.50

+1.80 (2.44%)

Oct 8, 2026, 1:30 PM CST

Market Cap	2.57B -16.9%
Revenue (ttm)	887.93M +8.9%
Net Income	185.79M +12.2%
EPS	5.40 +0.5%
Shares Out	34.07M
PE Ratio	13.99
Forward PE	n/a
Dividend	5.00 (6.62%)
Ex-Dividend Date	Mar 27, 2026

Volume	59,052
Open	73.60
Previous Close	73.70
Day's Range	73.60 - 76.40
52-Week Range	68.30 - 93.00
Beta	0.09
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About A Plus Biotechnology

A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of medical devices in Taiwan, China, and internationally. The company provides bone graft materials and other medical devices, as well as technical support services. It also offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, and biologics. In addition, the company provides trauma products, including internal fixation plates, screws, pins, intramedullary nails, cables, and external fixators... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2009

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6918

Full Company Profile

Financial Performance

In 2025, A Plus Biotechnology's revenue was 835.89 million, an increase of 8.61% compared to the previous year's 769.59 million. Earnings were 169.38 million, an increase of 12.13%.

Financial Statements